New developments in nitrosovasodilator therapy

Vascular Medicine

Volumn 2, Issue 3, 1997, Pages 190-202

  Leopold, Jane A ^a   Loscalzo, Joseph ^a,b  

^a BOSTON MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Nitric oxide; Nitric oxide donors; Nitrosovasodilators

Indexed keywords

BOVINE SERUM ALBUMIN; ENDOTHELIUM DERIVED RELAXING FACTOR; LINSIDOMINE; MOLSIDOMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITROGEN; NITROPRUSSIDE SODIUM; NITROSO DERIVATIVE; PIRSIDOMINE; PLACEBO; SINITRODIL; SPM 5185; SYDNONE DERIVATIVE; THIOL DERIVATIVE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BLOOD VESSEL TONE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG STRUCTURE; HEART MUSCLE REPERFUSION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TRANSPLANTATION; METHEMOGLOBINEMIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEPTIC SHOCK; VASODILATATION;

EID: 0030727358     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X9700200305     Document Type: Article

References (150)

1. Palmer RMJ, Ashton DS, Moncada V. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (London) 1988; 333: 664-66.
2. Nathan C Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6: 3051-64.
3. Bredt DS, Ferris CS, Snyder SH. Nitric oxide synthase regulatory sites. J Biol Chem 1992; 267: 10976-81.
4. Leone AM, Palmer RMJ, Knowles RG et al. Constitutive and inducible nitric oxide synthases incorporate molecular oxygen into both nitric oxide and citrulline. J Biol Chem 1991; 266: 23790-95.
5. Tayeh MA, Marletta MA. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J Biol Chem 1989; 264: 19654-58.
6. Stuehr DJ, Kwon NS, Nathan CF. FAD and GSH participate in macrophage synthesis of nitric oxide. Biochem Biophys Res Commun 1990, 168: 558-65.
7. White KA, Marietta MA Nitric oxide synthase is a cytochrome P-450 type hemoprotein. Biochem 1992, 31: 6627-31.
8. Drapier JC, Hibbs JB. Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cell results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J Immunol 1988; 140: 2829-38.
9. Stuehr DJ, Marietta MA. Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines or interferon. J Immunol 1987; 139: 518-25.
10. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. J Immunol 1988; 141: 2407-12.
11. Dinerman JL, Lowenstein CJ, Snyder SH Molecular mechanisms of nitric oxide regulation, Circ Res 1993; 73: 217-22.
12. Bredt DS, Snyder SH Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990; 87: 682-85.
13. Bruse R, Mulsch A. Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett 1990; 265: 133-36.
14. 2+-dependently converts L-arginine into an activator of soluble guanylyl cyclase. Biochem Biophys Res Commun 1989; 164: 678-85.
15. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989; 65: 1-21.
16. Qiao-Wen X, Hearn JC, Calaycay J et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 1992; 256: 599-604.
17. Welch G, Loscalzo J. Nitric oxide and the cardiovascular system. J Cardiac Surg 1994; 74: 1121-25.
18. Nathan C, Hibbs JB. Role of nitric oxide synthesis in macrophages antimicrobial activity. Curr Opin Immunol 1991; 3: 65-70.
19. Wang B, Lin PS, Tsao PS, Cooke JP Nitric oxide induces regression: role of apoptosis Circulation 1996; 94: I-155.
20. Regnasamy A, Johns RA. Regulation of nitric oxide synthase by nitric oxide. Mol Pharmacol 1993; 44: 124-28
21. Nishida K, Harrison DG, Navas JP et al. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest 1992; 90: 2092-96.
22. Leopold JA, Upchurch GR Jr, Welch G, Loscalzo J. Cyclic strain induces NO synthase in vascular smooth muscle cells. Circulation 1996; 94: 1-154.
23. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 258: 1898-902.
24. Stamler JS, Jaraki O, Osborne J et al Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992; 89: 7674-77.
25. Ignarro LJ. Signal transduction mechanisms involving nitric oxide. Biochem Pharmacol 1991; 41: 485-90.
26. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995; 37: 1-20.
27. Ignarro LJ, Adams JB, Horowitz PM et al. Activation of soluble guanylate cyclase by NO-hemoprotein involves NO-heme exchange. J Biol Chem 1986; 261: 4997-5002.
28. Ignarro LJ, Buga GM, Wood KS et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-69.
29. Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987; 92: 181-87.
30. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-26.
31. Ignarro LJ, Byrns RE, Buga GM et al. Endothelium-derived relaxing factor from pulmonary artery and vein possess pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987; 61: 866-79.
32. Mellion BT, Ignarro LJ, Ohlstein EH et al. Evidence or the inhibitory role of guanosine 3′5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57: 946-55.
33. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J 1989; 3: 31-36.
34. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989; 65: 1-21.
35. Kelm M, Schrader J. Control of coronary vascular tone by nitric oxide. Circ Res 1990; 66: 1561-75.
36. Shikano K, Ohlstein EH, Berkowitz BA. Differential selectivity of endothelium-derived relaxing factor and nitric oxide in smooth muscle. Br J Pharmacol 1987; 92: 483-85.
37. Hoefner U, Boulanger C, Vanhoutte PM. Proximal and distal dog coronary arteries respond differently to basal EDRF but not to NO. Am J Physiol 1989; 256: H828-31.
38. Myers PR, Minor RL, Guerra R et al. Vasorelaxant properties of endotlielium-derived relaxing factor more closely resembles S-nitroso-cysteine than nitric oxide Nature. 1990; 345: 161-63.
39. Scharfstein JS, Keaney JF, Slivka A et al. In vivo transfer of NO between a plasma-protein-bound reservoir and low molecular weight thiols. J Clin Invest 1994; 94: 1432-39.
40. Panza JA, Quyyumi AA, Brush JE et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27.
41. Radomski NW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 338: 1057-58.
42. Loscalzo J. Endothelial dysfunction in pulmonary hypertension. N Eng J Med 1992; 327: 117-19.
43. Liu SF, Crawley DE, Barnes PJ, Evans TW. Endothelium-derived relaxing factor inhibits hypoxic pulmonary vasoconstriction in rats. Am Rev Respir Dis 1991; 143: 32-37.
44. Gaston B, Reilly J, Drazen JM et al. Endogenous nitric oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci USA 1993; 90: 10956-61.
45. Pepke-Zaba J, Higgenbottom TW, Dinh Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991; 338: 1173-74.
46. Roberts JD Jr, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993; 87: 447-53.
47. Roissant R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328: 399-400.
48. Lefer AM, Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. Cardiovasc Res 1996; 32: 743-51.
49. Kanwar S, Kubes P. Nitric oxide is an antiadhesive molecule for leukocytes. New Horiz 1995; 3: 93-104.
50. Beckman JS, Beckman TW, Chen J et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and Superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-24.
51. Jayakody L, Senaratne MP, Thompson AB et al. Endothelium-dependent relaxation in experimental atherosclerosis in the rabbit. Circ Res 1987; 60: 251-64.
52. Creager MA, Cooke JP, Mendelsohn ME et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990, 86: 228-34.
53. Cohen RA, Zitnay KM, Hauderschild CC et al Loss of selective endothelial cell vasoactive functions caused by hypercholesterolemia in pig coronary arteries Circ Res 1988; 63: 903-10.
54. Lefer AM, Ma X-L. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to coronary artery endothelium. Atheroscler Thromb 1993, 13: 771-76.
55. Harrison DG, Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis, implications for impaired vasomotion. Am J Cardiol 1995; 75: 75-81B.
56. Dinerman JL, Mehta JL. Endothelial, platelet and leukocyte interactions in ischemic heart disease: insights into potential mechanisms and their clinical relevance. J Am Coll Cardiol 1990; 16: 207-22.
57. Fostermann U, Mugge A, Alheid U et al. Selective attenuation of endothelium mediated vasodilation in athersclerotic human coronary arteries. Circ Res 1988; 62: 185-90.
58. Persson MG, Agvald P, Gustafsson LE. Detection of nitric oxide in exhaled air during administration of nitroglycerin in vivo. Br J Pharmacol 1994; 111: 825-28.
59. 2 formation Biochem J 1993; 292: 545-50.
60. Fung H-L. Clinical pharmacology of organic nitrates. Am J Cardiol 1993; 72: 9C-15C.
61. Chung SH, Fung HL. Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. J Pharmacol Exp Ther 1990; 253: 614-19.
62. Chung SJ, Chong S, Seth P, Jung CY, Fung HL. Conversion of nitroglycerin to nitric oxide in microsomes of the bovine coronary smooth muscle is not primarily mediated by glutathione-S-transferases J Pharmacol Exp Ther 1992; 260: 652-59.
63. Harrison DG, Bates JN. The nitrosovasodilators: new ideas about old drugs. Circulation 1993; 87: 1461-67.
64. Fung HL, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc Drugs Ther 1994; 8: 489-99.
65. Boesgaard S, Aldershvile J, Poulsen HE, Loft S, Anderson ME, Meister A. Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ Res 1994; 74: 115-20.
66. Laursen JB, Mulsch A, Boesgaard S et al. In vivo nitrate tolerance is not associated with reduced bioconversion of nitroglycerin to nitric oxide. Circulation 1996; 94: 2241-4-7.
67. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular Superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995; 95: 187-94.
68. Fernandez R, Artigas A, Blanch L. Ventilatory factors affecting inhaled nitric oxide concentrations during continuous-flow administration. J Crit Care 1996; 11: 138-43.
69. Lowson SM, Rich GF, McArdle PA, Jaidev J, Morris GN. The response to varying concentrations of inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesth Analg 1996; 82: 574-81.
70. Channick RN, Newhart JW, Johnson FW, Moser KM. Inhaled nitric oxide reverses hypoxic pulmonary vasoconstriction in dogs. A practical nitric oxide delivery and monitoring system. Chest 1994; 105: 1842-47.
71. Mercer RR, Costa DL, Crapo JD. Effects of prolonged exposure to low closes of nitric oxide or nitrogen dioxide on the alveolar septa of the adult rat lung. Lab Invest 1995; 73: 20-28.
72. Tonz M, von Segesser LK, Schilling J et al. Treatment of acute pulmonary hypertension with inhaled nitric oxide. Ann Thorac Surg 1994; 58: 1031-35.
73. Zwissler B, Weite M, Messmer K. Effects of inhaled prostacyclin as compared with inhaled nitric oxide on right ventricular performance in hypoxic pulmonary vasoconstriction. J Cardiothor Vasc Anesth 1995; 9: 283-89.
74. Emil S, Kanno S, Berkeland J, Kosi M, Atkinson J. Sustained pulmonary vasodilation after inhaled nitric oxide for hypoxic pulmonary hypertension in swine. J Pediatr Surg 1996; 31: 389-93.
75. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997; 336: 597-604.
76. Roberts JD Jr, Fineman FR, Morin FC III et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997; 336: 605-610.
77. Hillman ND, Meliones JN, Black DR, Craig DM, Cheifetz IM, Smith PK In acute lung injury, inhaled nitric oxide improves ventilation-perfuison matching, pulmonary vascular mechanics, and transpulmonary vascular efficiency. J Thorac Cardiovasc Surg 1995; 110: 593-99.
78. Cheifetz IM, Craig DM, Kern FH et al. Nitric oxide improves transpulmonary vascular mechanics but does not change intrinsic right ventricular contractility in an acute respiratory distress syndrome model with permissive hypercapnia. Crit Care Med 1996; 24: 1554-61.
79. Rossaint R, Slama K, Steudel W et al. Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome. Intensive Care Med 1995; 21: 197-203.
80. Offner PJ, Ogura H, Jordan BS, Pruitt BA Jr, Cioffi WG Effects of inhaled nitric oxide on right ventricular function in endotoxin shock. J Trauma 1995; 39: 179-85.
81. McIntyre RC Jr, Moore FA, Moore EE, Piedalue F, Hansel JS, Fullerton DA. Inhaled nitric oxide variably improves oxygenation and pulmonary hypertension in patients with acute respiratory distress syndrome. J Trauma 1995; 39: 418-25
82. Roissant R, Gerlach H, Schmidt-Ruhnke H et al. Efficacy of inhaled nitric oxide in patients with severe ARDS. Chest 1995; 107; 1107-15.
83. Puybasset L, Rouby JJ, Mourgeon E et al. Factors influencing cardiopulmonary effects on inhaled nitric oxide in acute respiratory failure. Am J Respir Crit Care Med 1995, 152: 318-28.
84. Chollet-Martin S, Gatecel C, Kermarrec N, Gougerot-Pocidalo MA, Payen DM. Alveolar neutrophil functions and cytokine levels in patients with adult respiratory distress syndrome during nitric oxide inhalation. Am J Respir Crit Care Med 1996; 153: 985-90.
85. Moinard J, Manier G, Pillet O, Castaing Y. Effect of inhaled nitric oxide on hemodynamics and V/Q inequalities in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 149: 1482-87.
86. Barbera JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996; 347: 436-40.
87. Date H, Triantafillou AN, Trulock EP, Pohl MS, Cooper JD, Patterson GA. Inhaled nitric oxide reduces human lung allograft dysfunction. J Thorac Cardiovasc Surg 1996; 111: 913-19.
88. Okabayashi K, Triantafillou AN, Yamashita M et al. Inhaled nitric oxide improves lung allograft function after prolonged storage. J Thorac Cardiovasc Surg 1996; 112: 293-99.
89. Bacha EA, Herve P, Murakami S et al Lasting beneficial effect of short-term inhaled nitnc oxide on graft function after lung transplantation. Paris-Sud University Lung Transplantation Group. J Thorac Cardiovasc Surg 1996, 112: 590-98.
90. Vinten-Johansen J, Zhao ZQ, Sato H. Reduction in surgical ischemic-reperfusion injury with adenosine and nitric oxide therapy. Ann Thor Surg 1995; 60: 852-57.
91. Lefer AM. Attenuation of myocardial ischemia-reperfusion injury with nitric oxide replacement therapy. Ann Thor Surg 1995; 60: 847-51.
92. Semigran MJ, Cockrill BA, Kacmarek R et al. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994; 24: 982-92.
93. Hayward CS, Rogers P, Keogh AM, Kelly R, Spratt PM, Macdonald PS. Inhaled nitric oxide in cardiac failure: vascular versus ventricular effects. J Cardiovasc Pharmacol 1996; 27: 80-85.
94. Loh E, Stamler JS, Hare JM, Loscalzo J, Colucci WS. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994; 90: 2780-85.
95. Auler JO, Carmona MJ, Bocchi EA et al. Low doses of nitric oxide Ln heart transplant recipients. J Heart Lung Transplant 1996; 15: 443-50.
96. Weitzberg E, Rudehill A, Lundberg JM. Nitric oxide inhalation attenuates pulmonary hypertension and improves gas exchange in endotoxin shock. Eur J Pharmacol 1996; 233: 85-94.
97. Offner PJ, Ogura H, Jordan BS, Pruitt BA Jr, Cioffi WG. Cardiopulraonary effects of combined nitric oxide inhibition and inhaled nitric oxide in porcine endotoxic shock. J Trauma 1996; 41: 641-46.
98. Ogura H, Offner PJ, Saitoh D et al. The pulmonary effect of nitric oxide synthase inhibition following endotoxemia in a swine model. Arch Surg 1994; 129: 1233-39.
99. Scherrer U, Vollenweider L, Delabays A et al Inhaled nitric oxide for high-altitude pulmonary edema. N Engl J Med 1996; 334: 624-29.
100. Adrie C, Bloch KD, Morena PR et al Inhaled nitric oxide increases coronary artery patency after thrombolysis. Circulation 1996; 94: 1919-26.
101. Keaney J, Simon D, Stamler JS et al. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest 1993; 91: 1582-89.
102. Loscalzo J, Smick D, Andon N, Cooke J. S-Nitrosocaptopril. 1. Molecular characterization and effects on the vasculature and on platelets. J Pharmacol Exp Ther 1989; 249: 726-29.
103. Schaffer JE, Lee F, Thompson S, Han B, Cooke J, Loscalzo J. The hemodynamic effects of S-nitrosocaptopril in anesthetized dogs. J Pharmacol Exp Ther 1991; 256: 704-709.
104. Bauer JA, Fung HL. Differential hemodynamic effects and tolerance properties of nitroglycerin and an S-nitrosothiol in experimental heart failure. J Pharmacol Exp Ther 1991; 256: 249-54.
105. Marks DM, Vita JA, Folts JD, Kcaney JF Jr, Welch GN, Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest 1995; 96: 2630-38.
106. Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest 1985; 76: 703-708.
107. Mendelsohn M, O'Neill S, George D, Loscalzo J. Inhibition of fibrinogen binding to human platelets by S-nitroso-N-acetylcysteine. J Biol Chem 1990; 265: 19028-34.
108. Keaney JF, Stamler JS, Scharfstein JS, Loscalzo J. NO forms a stable adduct with serum albumin that has potent antiplatelet properties in vivo. J Clin Invest 1992; 40: 194 [abstract].
109. Langford EJ, Wainwright RJ, Martin JF. Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Arterioscler Thromb Vasc Biol 1996; 16: 51-55.
110. Gauthier TW, Davenpeck KL, Lefer AM. Nitric oxide attenuates leukocyte-endothelial interaction via P-selectin in splanchnic ischemia-reperfusion. Am J Physiol 1994; 267: G562-68.
111. Kubes P, Kurose I, Granger DN. NO donors prevent integrin-induced leukocyte adhesion but not P-selectin-dependent rolling in post-ischemic venules. Am J Physiol 1994; 267: H931-37.
112. Delyani JA, Nossuli TO, Scalia R, Thomas G, Garvey DS, Lefer AM. S-Nitrosylated tissue-plasminogen activator protects against myocardial ischemia-reperfusion injury in cats: role of the endothelium. J Pharmacol Exp Ther 1996; 279: 1174-80.
113. Morley D, Keefer LK. Nitric oxide/nucleophile complexes: a unique class of nitric oxide-based vasodilators. J Cardiovasc Pharmacol 1993; 22: S3-9.
114. Morley D, Maragos CM, Zhang X-Y, Boignon M, Wink DA, Keefer LK. Mechanism of vascular relaxation induced by the nitric oxide (NO)/nucleophile complexes, a new class of NO-based vasodilators. J Cardiovasc Pharmacol 1993; 21: 670-76.
115. Maragos CM, Morley D, Wink DA et al Complexes of NO with nucleophiles as agents for the controlled biological release of nitric oxide: vasorelaxant effects. J Med Chem 1991; 34: 3242-47.
116. Drago RS. Reactions of nitrogen (II) oxide. In. Colburn CB, ed Free radicals in inorganic chemistry Washington, DC: American Chemical Society, 1962: 143-49 (Advances in chemistry series, no. 36).
117. Diodati JG, Quyyumi AA, Keefer LK. Complexes of nitric oxide with nucleophiles as agents for the controlled biological release of nitric oxide: hemodynamic effect in the rabbit. J Cardiovasc Pharmacol 1993, 22: 287-92.
118. Mooradian DL, Hutsell TC, Keefer LK. Nitric oxide (NO) donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro. J Cardiovasc Pharmacol 1995; 25: 674-78.
119. Diodati JG, Quyyumi AA, Hussain N, Keefer LK. Complexes of nitric oxide with nucleophiles as agents for the controlled biological release of nitric oxide: antiplatelet effect. Thromb Haemost 1993; 70: 654-58.
120. Saavedra JE, Southan GJ, Davies KM et al. Localizing antithrombotic and vasodilatory activity with a novel, ultrafast nitric oxide donor. J Med Chem 1996; 39: 4361-65.
121. Smith DJ, Chakravarthy D, Pulfer S et al. Nitric oxide-releasing polymers containing the [N(O)NO]-group. J Med Chem 1996; 39: 1148-56.
122. Reden J. Molsidomine. Blood Vessels 1990; 27: 282-94.
123. Bath P. The effect of nitric oxide-donating vasodilators on monocyte chemotaxis nd intracellular cGMP concentrations in vitro. Eur J Clin Pharmacol 1993; 45: 53-58.
124. Feelisch M, Ostrowski J, Noack E. On the mechanism of NO release from sydnonimines. J Cardiovasc Pharmacol 1989; 14: 513-22.
125. Robak J, Gryglewski RJ. Nitric oxide donors as generators and scavengers of superoxide anions. Polish J Pharmacol 1993; 45: 51-58
126. Foucher-Lavergne A, Kolsky H, Spreux-Varoquaux O, Delonca J, Beaufils P. Hemodynamics, tolerability, and pharmacokinetics of linsidomine (SIN-1) infusion during the acute phase of uncomplicated myocardial infarction. J Cardiovasc Pharmacol 1993; 22: 779-84.
127. Anonymous. The ESPRIM trial: short-term treatment of acute myocardial infarction with molsidomine. European Study of Prevention of Infarct with Molsidomine. Lancer 1994; 344: 91-97.
128. Messin R, Boxho G, De Smedt J, Buntinx IM. Acute and chronic effect of molsidomine on exercise capacity in patients with stable angina, a double-blind cross-over clinical trial versus placebo. J Cardiovasc Pharmacol 1995; 25: 558-63.
129. Lablanche JM, Grollier G, Lusson JR et al. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Circulation 1997, 95: 83-89.
130. Bilinska M, Maczewski M, Beresewicz A Donors of nitric oxide mimic effects of ischaemic preconditioning on reperfusion induced arrhythmias in isolated rat heart. Mol Cell Biochem 1996; 160-161: 265-71.
131. Zhang F, Iadecola C. Reduction of focal cerebral ischemic damage by delayed treatment with nitric oxide donors. J Cereb Blood Flow and Metab 1994, 14: 574-80.
132. Zhang F, White JG, Iadecola C. Nitric oxide donors increase blood Sow and reduce brain damage in focal ischemia: evidence that nitric oxide is beneficial in the early stages of cerebral ischemia. J Cereb Blood Flow and Metab 1994; 14: 217-26
133. Groves PH, Lewis MJ, Cheadle HA, Penny WJ. SIN-1 reduces platelet adhesion and platelet thrombus formation in a porcine model of balloon angioplasty. Circulation 1993; 87: 590-97.
134. Wainwright CL, Martorana PA. Pirsidomine, a novel nitric oxide donor, suppresses ischemic arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol 1993; 22: S44-50.
135. Schini VB, Bond R, Gao S et al. The sydnonimine C87-3754 evokes endothelium-independent relaxations and prevents endothelium-dependent contractions in blood vessels of the dog. J Cardiovasc Pharmacol 1993; 22: S10-16.
136. La Rochelle CD, Dubois-Rande J-L, Richard V, Hittinger L, Guidicelli J-F, Berdeaux A. The role of NO release in the control of large and small coronary artery tone in conscious dogs. J Cardiovasc Pharmacol 1993; 22: S17-21.
137. Bassenge E, Zanzinger J. Effectiveness of an NO-releasing pirsidomine derivative on coronary conductance during long-term administration. J Cardiovasc Pharmacol 1993; 22: S22-26.
138. Lefer AM, Seigfried MR, Ma X-I. Protection of ischemia-reperfusion injury by sydnonimine NO donors via inhibition of neutrophil-endothelium interaction. J Cardiovasc Pharmacol 1993; 22: S27-33
139. Kita Y, Ohkubo K, Hirasawa Y et al FR 144420, a novel, slow, nitric oxide-releasing agent. Eur J Pharmacol 1995; 275: 125-30.
140. Cereda R, Bergamaschi M, Agozzino S et al. Protective effect of the nitrate ester ITF 296 against methacholine-induced myocardial ischemia in the anesthetized rat. J Cardiovasc Pharmacol 1995; 26: S37-43.
141. Duncker DJ, Mizrahi J, Bache RJ. Nitrosovasodilators ITF 296 and isosorbide dinitrate exert antiischemic activity by dilating coronary penetrating arteries. J Cardiovasc Pharmacol 1995; 25: 823-32
142. Rossoni G, Bert F, Bermareggi M et al. Protective effects of ITF 296 in the isolated rabbit heart subjected to global ischemia. J Cardiovasc Pharmacol 1995; 26: S44-52.
143. Arnet U, Yang Z, Siebenmann R et al. Development of nitrate tolerance in human arteries and veins: comparison of nitroglycerin and SPM 5185. J Cardiovasc Pharmacol 1993; 26: 401-406.
144. Guo JP, Milhoan KA, Tuan RS, Lefer AM. Beneficial effect of SPM-5185, a cysteine containing nitric oxide donor, in rat carotid artery intimal injury. Circ Res 1994; 75: 77-84.
145. Zanzinger J, Feelisch M, Bassenge E. Novel organic nitrates are potent dilators of large coronary arteries with reduced development of tolerance during long-term infusion in dogs, role of the sulfhydryl moiety. J Cardiovasc Pharmacol 1994; 23: 772-78.
146. Lefer DJ, Nakanishi K, Vinten-Johansen J. Endothelial and myocardial cell protection by a cysteine-containing nitric oxide donor after myocardial ischemia and reperfusion. J Cardiovasc Pharmacol 1993; 22: 34-43
147. Lefer DJ, Nakanishi K, Johnston WE, Vinten-Johansen J. Antineutrophil and myocardial protecting actions of a novel nitric oxide donor after acute myocardial ischemia and reperfusion of dogs. Circulation 1993; 88: 2337-50.
148. De Meyer GR, Bult H, Ustunes L, Kockx MM, Feelisch M, Herman AG Effect of nitric oxide donors on neointima formation and vascular reactivity in the collared carotid artery of rabbits. J Cardiovasc Pharmacol 1995; 26: 272-79.
149. Siegfried MR, Carey C, Xin-Liang X, Lefer AM. Beneficial effects of SPM-5185, a cysteine-containing NO donor, in myocardial ischemia-reperfusion. Am J Physiol 1992; 32: H771-77.
150. Hammon JW Jr, Vinten-Johnson J. Augmentation of microvascular nitric oxide improves myocardial performance following global ischemia J Cardiac Surg 1995; 10: 423-27.